MASS
908 Devices Inc.
MASS has slightly lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over MASS overall, supported by stronger fundamentals and stronger modeled upside.
MASS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Healthy | |
| Unavailable |
MASS's revenue and cash flow are currently healthy, but its profitability is weak. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MASS PE Valuation
MASS has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
MASS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect MASS's revenue to grow and its profitability to improve, with its earnings holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over MASS on the outlook, with more favorable earnings expectations.
MASS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.66 | -$0.53 |
| Q2 2026 | -$0.96 | -$0.40 |
| Q1 2026 | -$1.01 | -$0.45 |
| Q4 2025 | $0.54 | +$2.66 |
| Q3 2025 | -$0.13 | +$1.64 |
| Q2 2025 | -$0.56 | +$0.59 |
| Q1 2025 | -$0.56 | +$0.51 |
| Q4 2024 | -$2.12 | -$0.99 |
MASS is still losing money, but far less than before: $0.66 per share over the past year, against $2.12 at its worst in late 2024.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over MASS on earnings quality, reporting a profit while its opponent remains loss making.
MASS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19M | +35% |
| Q2 2026 | $16.1M | +23% |
| Q1 2026 | $13.4M | +14% |
| Q4 2025 | $17.4M | -7.7% |
| Q3 2025 | $14M | -17% |
| Q2 2025 | $13M | -7.2% |
| Q1 2025 | $11.8M | +18% |
| Q4 2024 | $18.8M | +31% |
MASS's revenue is growing: $19M last quarter, up 35% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -29% | +88 points |
| Q2 2026 | -80% | +37 points |
| Q1 2026 | -96% | -2.7 points |
| Q4 2025 | 18% | +125 points |
| Q3 2025 | -117% | +64 points |
| Q2 2025 | -116% | -20 points |
| Q1 2025 | -94% | +33 points |
| Q4 2024 | -108% | -40 points |
MASS's operating margin was −29% last quarter, up 88 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MASS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over MASS on profitability, with a higher operating margin.
MASS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.9M | +$2M |
| Q2 2026 | $3M | +$8.9M |
| Q1 2026 | $1.2M | +$16.3M |
| Q4 2025 | $1.3M | +$3.8M |
| Q3 2025 | -$4.9M | +$879K |
| Q2 2025 | -$5.9M | +$6.5M |
| Q1 2025 | -$15.2M | -$4.9M |
| Q4 2024 | -$2.4M | -$170K |
MASS's free cash flow has turned positive after six years mostly in the red: $3M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
MASS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8.9% | +3.3M shares |
| 1 year | +14% | +5M shares |
| 3 years | +27% | +8.7M shares |
| 5 years | +48% | +13.4M shares |
| Available history | +492% | +34.1M shares |
MASS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MASS Net Leverage
MASS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
MASS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.5 | Neutral |
| Stochastic | 46.7 | Neutral |
MASS's weekly RSI is 51 (neutral) and its Stochastic is 47 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MASS PE vs Healthcare Sector
MASS has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
MASS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.3 | 14% below |
| 20 week MA | $10.0 | 2.2% below |
| 50 week MA | $8.06 | 21% above |
| 100 week MA | $6.71 | 46% above |
| 200 week MA | $6.59 | 49% above |
MASS has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 49% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over MASS on trend strength, trading above more of its moving averages.
MASS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $49.0 | $67.9 | +39% |
| 2021 | $67.9 | $26.6 | -61% |
| 2022 | $26.6 | $7.31 | -73% |
| 2023 | $7.31 | $11.2 | +53% |
| 2024 | $11.2 | $2.26 | -80% |
| 2025 | $2.26 | $5.41 | +139% |
| 2026 YTD | $5.41 | $9.79 | +81% |
MASS's yearly returns have swung widely, from +139% in 2025 to −80% in 2024. It's up 81% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MASS on returns for 2026, with the stronger performance.